Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzonitrile. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 4/20 | 0.56 |
| ▸ | MAOA known ✓ | P21397 | 3/20 | 0.56 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.48 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.93 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzonitrile SCHEMBL16899036 | 1.00 | TSHR (0.93) | TSHRMAOBMAOAAPPALDH1A1 | |
| Benzonitrile SCHEMBL2904373 | 1.00 | — | — | |
| Benzonitrile SCHEMBL27506476 | 1.00 | TSHR (0.93) | TSHRMAOBMAOAAPPALDH1A1 | |
| Hydrochloric Acid SCHEMBL7996155 | 1.00 | TSHR (0.93) | TSHRMAOBMAOAAPPALDH1A1 | |
| Benzonitrile SCHEMBL3852661 | 1.00 | TSHR (0.93) | TSHRMAOBMAOAAPPALDH1A1 | |
| Benzonitrile SCHEMBL17107360 | 1.00 | TSHR (0.93) | TSHRMAOBMAOAAPPALDH1A1 | |
| Benzonitrile SCHEMBL4126283 | 1.00 | TSHR (0.93) | TSHRMAOBMAOAAPPALDH1A1 | |
| Benzonitrile SCHEMBL3082428 | 0.97 | TSHR (0.88) | TSHRMAOBMAOAAPPALDH1A1 | |
| Benzonitrile SCHEMBL3650085 | 0.97 | TSHR (0.88) | TSHRMAOBMAOAAPPALDH1A1 | |
| Benzonitrile SCHEMBL3056732 | 0.97 | TSHR (0.88) | TSHRMAOBMAOAAPPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118388307-A | Method for synthesizing bicyclopropenyl high-energy fuel with high selectivity | 龙子湖新能源实验室 | 2024-07-26 | — | — | CN | claimed |
| CN-112679292-A | Synthesis method of secondary sulfonamide compound | 复旦大学 | 2021-04-20 | — | — | CN | claimed |
| CN-111434650-A | Aromatic pyridazine coordination compound, preparation method and application thereof | 天津大学 | 2020-07-21 | — | — | CN | claimed |
| EP-0758333-B1 | INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION | OSI PHARM INC (US) | 2004-03-03 | — | — | EP | claimed |
| EP-0758333-A1 | INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION | GLAXO WELLCOME INC. (US) | 1997-02-19 | — | — | EP | claimed |
| US-5491237-A | Intermediates in pharmaceutical camptothecin preparation | GLAXO WELLCOME INC. (US) | 1996-02-13 | — | — | US | claimed |
| WO-1995029917-A2 | INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION | GLAXO WELLCOME INC. (US) | 1995-11-09 | — | — | WO | claimed |
| EP-4143158-A1 | PREPARATION OF AROMATIC CARBOXYAMIDES BY PALLADIUM-CATALYZED CARBONYLATION REACTION | BASF SE (DE) | 2023-03-08 | — | — | EP | disclosed |
| CN-112566631-A | Amidines and amidine analogs for the treatment of bacterial infections and potentiation of antibiotics | 乔治亚州大学研究基金会 | 2021-03-26 | — | — | CN | disclosed |
| CN-111434650-A | Aromatic pyridazine coordination compound, preparation method and application thereof | 天津大学 | 2020-07-21 | — | — | CN | disclosed |
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2479168-A1 | 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists | ELI LILLY AND COMPANY (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-6531485-B2 | For therapy of bone disorders including osteoporosis | PFIZER INC. | 2003-03-11 | — | — | US | disclosed |
| US-20030008895-A1 | PROSTAGLANDIN AGONISTS | CAMERON KIMBERLY O (US) | 2003-01-09 | — | — | US | disclosed |
| EP-1272270-A2 | METHOD FOR THE PRODUCTION OF ALCOHOLS ON RHENIUM-CONTAINING ACTIVATED CHARCOAL SUPPORTED CATALYSTS | BASF AKTIENGESELLSCHAFT (DE) | 2003-01-08 | — | — | EP | disclosed |
| US-6441186-B1 | ANTICANCER AGENTS; PREVENTION OF MITOSIS THROUGH INDUCTION AND STABILIZATION OF MICROTUBULIN ASSEMBLY; SUPERIOR CYTOTOXIC ACTIVITIES | THE SCRIPPS RESEARCH INSTITUTE | 2002-08-27 | — | — | US | disclosed |
| WO-2001070657-A2 | METHOD FOR THE PRODUCTION OF ALCOHOLS ON RHENIUM-CONTAINING ACTIVATED CHARCOAL SUPPORTED CATALYSTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-27 | — | — | WO | disclosed |
| EP-0944634-A1 | EPOTHILONE ANALOGS | Novartis AG (CH) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025929-A1 | EPOTHILONE ANALOGS | NOVARTIS AG (CH) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008895-A1 | PROSTAGLANDIN AGONISTS | PTGER1, PTGER4, PTGIR | MAOB 2002/4885MAOA 1332/4885CA2 3521/4885 |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | HTR2C, HTR4, HTR1A | MAOB 194/4885MAOA 170/4885CA2 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.